Biochemical and clinical safety of Nomegestrol acetate administered alone then associated sequentially with 17 beta estradiol in inversed sequence inwomen with dyslipoproteinemia classified IIa

In this study including 26 patients with dyslipoproteinemia classified IIa, we evaluated biochemical and clinical safety of Nomegestrol acetate (Luten yl(R)) used for its antigonadotrophin property. It was administered alone, during 3 cycles at the dose of 5 mg/d for 21 days by cycle and then it was associated (at the same sequence and dose), without any wash out, for the n ext 6 cycles, with a 17 beta estradiol patch (Estraderm(R) TTS 50), 50 mu g /d from the 11th to the 21st day of each cycle. Nomegestrol acetate, alone, had no significant effect on glycemia, antithro mbin III, triglycerides, total cholesterol, apoprotein A1, and LpA1 values compared to those at baseline but apoprotein B and Lp (a) values tended to decrease slightly. Serum progesterone levels were collapsed, and FS values were low. Weight and blood pressure remained constant. Adding 17 beta estradiol enabled to significantly decrease and normalize th e apoprotein B values after the first 3 cycles compared to the baseline val ues, then these values remained constant during the next 3 cycles. There was no effect on the other parameters (except for a significant incre ase in plasmatic estradiol values) on the antigonadotrophin property on Nom egestrol acetate, nor on eight and blood pressure which remained constant. Moreover, we observed an important decrease in the rate of amenorrheic cycl es compared to those with Nomegestrol acetate alone.